Equipoise is the brand name of the anabolic steroid Boldenone. It is an oil-based injectable with an added undecylenate ester. Added ether helps increase half-life and release rate. The substance is a derivative of testosterone with symmetrical anabolic power, but with a reduced androgenic effect. Equipoise is a drug used in veterinary medicine. But it has gained popularity among bodybuilders and athletes as a form of testosterone, a derivative with less estrogenic and androgenic activity. They like to compare Equipoise to Nandrolone (Deca-Durabolin), but it’s not the best comparison because Nandrolone has different properties and a completely different class of compounds (19-nor or progestin). However, many consider Equipoise and Nandrolone to be interchangeable drugs, even in anabolic steroid cycles.

Description and history of the drug

history of the drug

Equipoise was developed in 1949, before Dianabol (Methandrostenolone), which technically makes it the first synthetic testosterone derivative. Also, Dianabol itself is actually Equipoise (Boldenone). The difference is in the chemical structure where the methyl group is attached to the 17-beta hydroxyl (also known as C17-alpha alkylation). This structure makes the substance bioavailable orally. In general, Dianabol could be considered an oral form of equilibrium, but the methylation of the 17th carbon atom changed the properties of the compound so much that it began to be attributed to completely different anabolic steroid analogues and was called Methandrostenolone (Dianabol).

Drug properties

Drug properties

As Equipoise is derived from testosterone, this gives it many symmetrical properties. First, it has exactly the same degree of anabolic potency (index 100). Second, Equipoise is an aromatizable anabolic steroid, and through the interaction in the body with the aromatase enzyme, it can be converted into estrogen. The modification with a double bond between carbon atoms 1 and 2 reduces its ability to aromatize and therefore provides less estrogenic activity of Equipoise in the body.

All of this means that Equipoise converts to estrogen, but in much lower amounts than its parent hormone, testosterone. This positive property does not exclude the manifestation of estrogenic side effects, which should be taken into account when taking the drug. Therefore, do not expect Equipoise to not retain water in the body. This will only happen to a relatively minor extent. Of course, everything is individual and depends on the sensitivity of the body to the drug. But, in moderate doses, Equipoise should not cause water retention in the body or any other negative manifestations. At the same time, the risk of side effects will increase as the dose of the drug increases, since an increase in the equilibrium concentration in the body will symmetrically increase the rate of aromatization to estrogen.

The drug Equipoise itself is characterized by a low level of androgenic strength (lower than that of the parent hormone, testosterone). Such a positive moment is important for people sensitive to the manifestations of even minor androgenic side effects. With Equipoise, one can expect gains in strength, volume, and mass that are symmetrical to those achieved with testosterone, but with less evidence of estrogenic activity and androgenic side effects. This means that the benefits of Equipoise, for the most part, will be fairly solid dry weight gain with minimal water retention (depending on dosage). It will be the perfect addition to any volume or muscle growth class. And in some courses, Equipoise can even become a substitute for Nandrolone. Unlike nandrolone, Equipoise is not a progestogen and has fewer side effects of suppressing natural testosterone production.

It is important to understand that the drug will not give rapid muscle growth, the process will be much slower compared to other anabolic steroids, but the long term results and the absence of side effects when used correctly are the obvious advantages of Equipoise.

Side effects

Side effects

As mentioned above, Equipoise exhibits less estrogenic activity in the body than testosterone. Equipoise aromatizes in the body at about half the rate of aromatization that testosterone exhibits. This means that the side effects associated with Equipoise should be significantly lower than those of testosterone. But here it is important to remember that the estrogenic activity of Equipoise will be slightly higher than that of Nandrolone (Deca). Of course, if you increase the dosage, the aromatization (and, therefore, the estrogenic effect) will increase proportionally. In such cases, anti-estrogens and aromatase inhibitors will be needed to help prevent the manifestation of negative factors. Estrogenic side effects may include: fluid retention, increased blood pressure (due to fluid retention), increased body fat percentage (increased body fat), and potential development of gynecomastia.

Androgenic side effects, although to a much lesser degree than testosterone, are still possible with Equipoise. It interacts with the enzyme 5-AR (5-alpha reductase), which is responsible for converting testosterone into the more potent androgen DHT (dihydrotestosterone). Equipoise does not convert to DHT, but rather converts to dihydroboldenone (DGB) at a much slower rate than testosterone to DHT. Androgenic side effects may include: oilier skin (sebum secretion), increased acne (associated with sebum secretion), body and facial hair growth and (if predisposed genetics) an increased risk of male pattern baldness.

Equipoise is non-toxic, does not affect the liver, and is associated with the same degree of cardiovascular disease risk and suppression of endogenous testosterone production as most anabolic steroids.

Back to top